Analyzing non-coding RNA in patients with acute ischemic stroke
Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)
Nanjing First Hospital, Nanjing Medical University · NCT04175691
This study is trying to see if certain types of non-coding RNA in the blood can help doctors better detect and understand the outcomes of patients who have had an acute ischemic stroke.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nanjing First Hospital, Nanjing Medical University (other) |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT04175691 on ClinicalTrials.gov |
What this trial studies
This study investigates the expression patterns of circular RNA (circRNA), micro-RNA (miRNA), and long non-coding RNA (lncRNA) in patients diagnosed with acute ischemic stroke compared to healthy controls. Using next-generation sequencing, the study aims to identify distinctive expression patterns of these non-coding RNAs that may serve as biomarkers for the detection and prognosis of acute ischemic stroke. The findings will be validated through quantitative real-time polymerase chain reaction (qRT-PCR) and a diagnostic model will be developed using logistic regression to assess the clinical significance of these biomarkers.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years or older who have been diagnosed with acute ischemic stroke within 72 hours of symptom onset.
Not a fit: Patients with a history of hemorrhagic infarction, chronic kidney or liver diseases, peripheral arterial occlusive disease, active malignant disease, or inflammatory or infectious diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of novel biomarkers for the early detection and prognosis of acute ischemic stroke.
How similar studies have performed: While the exploration of non-coding RNAs in stroke is a growing field, this specific approach using next-generation sequencing for acute ischemic stroke biomarkers is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 years or older * Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan * Within 72 hours of symptom onset * Good performance status * Signed an approved informed consents Exclusion Criteria: -a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases
Where this trial is running
Nanjing, Jiangsu
- Nanjing First Hospital, Nanjing Medical University — Nanjing, Jiangsu, China (RECRUITING)
Study contacts
- Study coordinator: Junshan Zhou, M.D.
- Email: zhjsh333@126.com
- Phone: +8602587726218
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Stroke, Ischemic Stroke, acute ischemic stroke, noncoding RNA, clinical significance, outcome